Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Key Points

• Personalis (NASDAQ: PSNL) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a more favorable outlook for the company's stock.
• Analysts have set varied price targets for Personalis, with a range from $6.00 by BTIG Research to $8.50 by HC Wainwright, indicating a consensus average target of $7.42.
• Institutional investment in Personalis has increased significantly, with American Century Companies raising its holdings by 33.9% and BNP Paribas Financial Markets increasing its holdings by an astonishing 53,126.7%.

Personalis (NASDAQ:PSNL - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Several other research analysts have also recently commented on PSNL. HC Wainwright reissued a "buy" rating and set a $8.50 price target on shares of Personalis in a research report on Monday, September 8th. BTIG Research set a $6.00 price objective on Personalis in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $7.42.

Personalis Stock Performance

NASDAQ PSNL traded up $0.11 during trading hours on Friday, hitting $6.27. 86,283 shares of the company traded hands, compared to its average volume of 1,039,163. The business's 50-day moving average is $5.40 and its 200-day moving average is $4.94. Personalis has a twelve month low of $2.83 and a twelve month high of $7.79. The stock has a market capitalization of $555.85 million, a price-to-earnings ratio of -4.90 and a beta of 1.76.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%.The firm had revenue of $17.20 million during the quarter, compared to analysts' expectations of $20.12 million. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PSNL. Ameriprise Financial Inc. lifted its holdings in shares of Personalis by 38.3% in the fourth quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock valued at $199,000 after purchasing an additional 9,535 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Personalis by 53,126.7% in the fourth quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company's stock valued at $415,000 after purchasing an additional 71,721 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Personalis by 86.1% in the fourth quarter. Two Sigma Investments LP now owns 145,662 shares of the company's stock valued at $842,000 after purchasing an additional 67,403 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Personalis by 25.6% in the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock valued at $198,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in shares of Personalis by 438.7% in the fourth quarter. Squarepoint Ops LLC now owns 91,684 shares of the company's stock valued at $530,000 after purchasing an additional 74,664 shares in the last quarter. Institutional investors own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.